```html

Immune Thrombocytopenic Purpura (ITP) – A Comprehensive Patient Guide

Overview

Immune thrombocytopenic purpura (ITP) is an acquired autoimmune disorder in which the body’s immune system mistakenly attacks and destroys platelets—cell fragments that are essential for normal blood clotting. The resulting low platelet count (thrombocytopenia) can cause easy bruising, petechiae (tiny red spots on the skin), nosebleeds, gum bleeding, and, in severe cases, life‑threatening internal bleeding.

Who it affects: ITP can develop at any age, but the epidemiology shows two peaks:

• Children – about 5–8 cases per 100,000 per year, often following a viral infection and frequently resolving spontaneously.
• Adults – approx. 3–4 cases per 100,000 per year; the disease tends to be chronic and more common in women (2–3 : 1 female‑to‑male ratio).

Overall, roughly 1–2 million people in the United States live with ITP, and prevalence is similar worldwide (≈ 0.01‑0.02 % of the population).<sup>1</sup>

Symptoms

Symptoms correlate with how low the platelet count falls and can vary from none (asymptomatic) to severe bleeding. Below is a comprehensive list:

• Petechiae: Tiny, flat red or purple spots (≤ 2 mm) that appear on the skin, especially on the arms, legs, and trunk.
• Purpura / Ecchymoses: Larger bruises (≥ 5 mm) that develop without obvious trauma.
• Nosebleeds (epistaxis): Frequent or prolonged bleeding from the nostrils.
• Bleeding gums: Spontaneous bleeding while brushing or chewing.
• Heavy menstrual bleeding (menorrhagia): Particularly important in women of reproductive age.
• Blood in urine (hematuria) or stool (melena): Sign of bleeding in the urinary or gastrointestinal tract.
• Prolonged bleeding from cuts or after dental work.
• Headache, visual changes, or neurological deficits: May indicate intracranial bleeding – a medical emergency.
• Fatigue and weakness: Usually related to chronic anemia from occult bleeding.

Causes and Risk Factors

Underlying Mechanism

ITP is primarily an autoimmune process:

• Auto‑antibodies (most commonly IgG) bind to platelet surface glycoproteins (e.g., GPIIb/IIIa).
• The antibody‑coated platelets are destroyed by macrophages in the spleen and liver.
• In addition, impaired platelet production in the bone marrow can occur due to antibody‑mediated inhibition of megakaryocytes.

Known Triggers

• Acute infections: Particularly viral (e.g., Epstein‑Barr virus, cytomegalovirus, HIV, hepatitis C). In children, the disease often follows a respiratory or gastrointestinal virus.
• Medications: Certain drugs can induce ITP‑like thrombocytopenia (e.g., quinine, heparin‑induced thrombocytopenia, alpha‑interferon, some antibiotics).
• Vaccinations: Rarely, vaccines (e.g., MMR, COVID‑19) have been temporally associated with ITP, usually self‑limited.
• Other autoimmune diseases: Systemic lupus erythematosus, Sjögren’s syndrome, and antiphospholipid syndrome increase risk.

Risk Factors

• Female gender (especially reproductive age).
• History of another autoimmune condition.
• Recent viral infection or certain medications.
• Family history of autoimmune disease (genetic predisposition).

Diagnosis

Diagnosing ITP is one of exclusion—ruling out other causes of low platelets.

Initial Evaluation

• Complete Blood Count (CBC) with peripheral smear: Isolated thrombocytopenia (platelets < 150 × 10⁹/L) with normal red and white cells.
• Medical history & physical exam: Look for signs of bleeding, recent infections, drug exposure, and splenomegaly (enlarged spleen suggests alternative diagnoses).

Laboratory Tests to Exclude Other Causes

• Basic metabolic panel, liver function tests (to rule out liver disease).
• Serologic tests for HIV, hepatitis C, and hepatitis B.
• Antinuclear antibody (ANA) panel if autoimmune disease is suspected.
• Coagulation studies (PT/INR, aPTT) – typically normal in ITP.

Specialized Tests (often not required)

• Bone marrow aspirate/biopsy: Reserved for patients > 60 years, those with atypical findings, or when malignancy is a concern. In ITP, cellularity is usually normal or increased with normal megakaryocytes.
• Platelet antibody assays: Not routinely used because of low sensitivity/specificity.

Diagnostic Criteria (per American Society of Hematology)

1. Platelet count < 100 × 10⁹/L.
2. Absence of another identifiable cause of thrombocytopenia.
3. Typical clinical presentation (purpura, mucosal bleeding, etc.).

Treatment Options

Treatment decisions balance platelet count, bleeding severity, patient age, comorbidities, and personal preferences.

First‑Line Therapies

• Corticosteroids: Prednisone 1 mg/kg/day (or dexamethasone 40 mg daily for 4 days). They dampen antibody production. Taper slowly to avoid relapse.
• Intravenous Immunoglobulin (IVIG): 1 g/kg daily for 1–2 days. Provides rapid, temporary platelet rise—useful when urgent bleeding control is needed.
• Anti‑D immunoglobulin (RhIG): For Rh‑positive, non‑splenectomized patients; works similarly to IVIG.

Second‑Line / Chronic Management

• Rituximab: Anti‑CD20 monoclonal antibody; depletes B‑cells producing auto‑antibodies. Given weekly for 4 weeks. About 60 % achieve durable remission, but infections are a risk.
• Thrombopoietin receptor agonists (TPO‑RAs):
  • Eltrombopag – oral, 25–75 mg daily.
  • Romiplostim – weekly subcutaneous injection.
  Both stimulate platelet production; they are now standard for adults with refractory ITP.
• Splenectomy: Surgical removal of the spleen eliminates the primary site of platelet destruction. Success rates 60‑70 % for long‑term remission, but increased lifelong infection risk; therefore, usually reserved after failure of medical therapy.
• Immunosuppressants: Azathioprine, mycophenolate mofetil, or cyclosporine may be used in select cases.

Supportive Care

• Platelet transfusion – only for life‑threatening hemorrhage or before surgery; transfused platelets are rapidly destroyed unless the underlying immune activity is controlled.
• Tranexamic acid – topical or oral, for mucosal bleeding.
• Folic acid supplementation – to support marrow recovery.

Lifestyle & Non‑Pharmacologic Measures

• Avoid aspirin, NSAIDs, and any anticoagulants unless prescribed.
• Use soft toothbrushes, avoid flossing aggressively.
• Wear protective gear during contact sports.
• Maintain a balanced diet rich in iron and vitamin C to support overall blood health.

Living with Immune Thrombocytopenic Purpura

Daily Management Tips

• Monitor platelet counts: Regular CBCs as advised (often every 1–3 months once stable).
• Bleeding awareness: Keep a bleeding diary – note nosebleeds, gum bleeding, bruises, menstrual flow.
• Medication review: Share your ITP diagnosis with every prescriber; many over‑the‑counter drugs can worsen bleeding.
• Vaccinations: Get the annual flu shot, COVID‑19 booster, and pneumococcal vaccine, especially if you have had a splenectomy or are on immunosuppressants.
• Dental care: Schedule regular dental check‑ups; inform the dentist of your platelet level before procedures.
• Travel & emergencies: Carry a card or bracelet stating “Immune Thrombocytopenic Purpura – may require platelet transfusion.” Bring a recent CBC copy when traveling.
• Psychological support: Chronic ITP can cause anxiety. Support groups, counseling, or online communities (e.g., ITP Support Association) are valuable.

Reproductive Health

Women with ITP should discuss pregnancy plans with a hematologist and obstetrician. Most can have successful pregnancies, but platelet counts need close monitoring; steroids or IVIG are preferred treatments during pregnancy, while TPO‑RAs are used cautiously.

Prevention

Because ITP is largely autoimmune, primary prevention is limited. However, risk can be reduced by:

• Prompt treatment of infections that are known triggers (e.g., HIV, hepatitis C).
• Avoiding unnecessary medications that may precipitate drug‑induced thrombocytopenia.
• Maintaining an up‑to‑date vaccination schedule to prevent infections that could trigger ITP.
• Practicing good hand hygiene and safe sex to reduce exposure to viral illnesses.

Complications

If left untreated or poorly controlled, ITP can lead to serious outcomes:

• Severe hemorrhage: Intracranial, gastrointestinal, or intra‑articular bleeding.
• Chronic anemia: From ongoing low‑grade blood loss.
• Treatment‑related complications: Long‑term steroids → osteoporosis, diabetes, cataracts; splenectomy → overwhelming post‑splenectomy infection (OPSI); immunosuppressants → opportunistic infections.
• Pregnancy complications: Placental abruption, pre‑eclampsia, or neonatal thrombocytopenia.

When to Seek Emergency Care

---

Sources: 1. Mayo Clinic. Immune thrombocytopenic purpura (ITP). www.mayoclinic.org. 2. American Society of Hematology. Guidelines for ITP. ash.org. 3. CDC. Platelet Disorders. cdc.gov. 4. NIH National Heart, Lung, and Blood Institute. ITP Fact Sheet. nhlbi.nih.gov. 5. Cleveland Clinic. Immune Thrombocytopenic Purpura (ITP) Overview. my.clevelandclinic.org.

```